329911-76-4

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 771-61-9 2,3,4,5,6-pentafluorophenol 
• 288851-44-5 4-(4-tert-butoxycarbonyl-piperazin-1-yl)-4-oxobutanoic acid 

Downstream Products

• 858555-32-5 m-[4-oxo-4-(4-Boc-piperazin-1-yl)butyrylamino]-benzoic acid 
• 801317-53-3 4-oxo-4-(4-Boc-piperazin-1-yl)butyryl-glycyl-L-aspartyl-L-phenylalanine 
• 801317-51-1 4-oxo-4-(4-Boc-piperazin-1-yl)butyrylglycine pentafluorophenyl ether 
• 329911-79-7 (4-[4-tert-butoxycarbonyl-piperazin-1-yl)-4-oxobutyryl]glycyl-D,L-β-phenyl-β-alanine 
• 858555-40-5 m-[4-oxo-4-(4-Boc-piperazin-1-yl)butyrylamino]benzoyl-β-(3,4-methylenedioxyphenyl)-β-alanine 
• 858555-36-9 succinimidyl m-[4-oxo-4-(4-Boc-piperazin-1-yl)butyrylamino]benzoate 
• 329911-78-6 methyl (4-[4-tert-butoxycarbonyl-piperazin-1-yl)-4-oxobutyryl]glycyl-D,L-β-phenyl-β-alaninate 

Relevant academic research and scientific papers

Synthesis and antiaggregative activity of a new RGDF mimetic

m-[4-Oxo-4-(piperazin-1-yl)butyrylamino)benzoyl-D,L-β-(3, 4-methylenedioxyphenyl)-β-alanine, a new mimetic of the peptide RGDF, was synthesized. This compound inhibited ADP-induced platelet aggregation in human blood plasma enriched with platelets with IC

Synthesis and antiaggregation activity of a new RGDF peptidomimetic

A new RGDF peptidomimetic, [4-oxo-4-(pyperazin-1-yl)butyryl]glycyl-D,L-β-phenyl-β-alanine was synthesized. The arginyl mimetic used was the 4-oxo-4-(piperazin-1-yl)butanoic acid residue, and the Asp-Phe chain is replaced by a β-phenyl-β-alanine residue. The synthesized pseudopeptide showed ability to inhibite ADF-induced thrombocyte aggregation in a thrombocyte-rich rat blood plasma (IC50 8.7 × 10-9 M).